当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Yawei Luo
Drug Repurposing opportunities arise from potential observations, discussions, and collaborations, including the development of different meaningful platforms for the identification of drugs and their potential targets and allow the accessing of compounds. Drug Repurposing is an approach that uses the existing approved/failed drug for novel clinical use. This approach has the advantage that the compounds have already undergone different drug discovery phases and have sufficient information related to safety, efficacy, formulation, dose, and potential toxicity. As a result, this strategy is gaining considerable attention in drug research because of its cost-effective and time-saving capabilities. In recent years many pharmaceuticals are utilizing this approach for their drug discovery and development program, in fact in the Covid-19 era, its utility increased by many folds.